Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data
Top Cited Papers
- 31 March 2009
- journal article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 10 (3), 233-239
- https://doi.org/10.1016/s1470-2045(08)70340-1
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate CancerClinical Cancer Research, 2008
- Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experienceAnnals of Oncology, 2008
- Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2008
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working GroupJournal of Clinical Oncology, 2008
- Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate CancerClinical Cancer Research, 2007
- A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastatic Prostate Cancer: A TAX327 Study AnalysisClinical Cancer Research, 2007
- Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trialsNature Clinical Practice Oncology, 2006
- Prostate Cancer Clinical Trial End Points: “RECIST”ing a Step BackwardsClinical Cancer Research, 2005
- Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast CancerThe New England Journal of Medicine, 2004
- Graphical Methods for Censored DataJournal of the American Statistical Association, 1991